Key Documents

Levonorgestrel

Name: Levonorgestrel
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

D(−)-Norgestrel, 13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₂₁H₂₈O₂

CAS Number:

797-63-7

Molecular Weight:

312.45

NACRES:

NA.24

PubChem Substance ID:

329750050

UNSPSC Code:

41116107

MDL number:

MFCD00199013

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

levonorgestrel

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

WWYNJERNGUHSAO-XUDSTZEESA-N

Gene Information

human ... PGR(5241)

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levonorgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	BP501	PHR1850	Y0001618
USP 1362602 Levonorgestrel	BP501 Levonorgestrel	Supelco PHR1850 Levonorgestrel	Y0001618 Levonorgestrel for system suitability 2
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard	grade pharmaceutical primary standard
manufacturer/tradename USP	manufacturer/tradename BP	manufacturer/tradename -	manufacturer/tradename EDQM
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical pharmaceutical small molecule	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)
format neat	format neat	format neat	format neat
Gene Information human ... PGR(5241)	Gene Information human ... PGR(5241)	Gene Information human ... PGR(5241)	Gene Information human ... PGR(5241)
API family levonorgestrel	API family levonorgestrel	API family levonorgestrel	API family levonorgestrel

Still not finding the right product?

Explore all of our products under Levonorgestrel

pictograms

GHS08

signalword

Danger

hcodes

H351,H360D,H362

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable

pcodes

P202 - P260 - P263 - P264 - P280 - P308 + P313

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pericoital oral contraception with levonorgestrel: a systematic review.

Elizabeth G Raymond et al.

Obstetrics and gynecology, 117(3), 673-681 (2011-02-24)

To determine the effectiveness and safety of repeated precoital and postcoital use of levonorgestrel for pregnancy prevention. We searched eight computerized databases for studies that evaluated oral hormones taken for contraception immediately before or after each coital act during one

Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis.

Woraluk Somboonporn et al.

Menopause (New York, N.Y.), 18(10), 1060-1066 (2011-07-02)

The objective of this study was to compare the effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) with those of systemic progestogen in perimenopausal and postmenopausal women taking systemic estrogen therapy (ET). We searched Medline (August 8, 2009), Embase (August 8

Hemoglobin and serum ferritin levels in women using copper-releasing or levonorgestrel-releasing intrauterine devices: a systematic review.

Richard F Lowe et al.

Contraception, 87(4), 486-496 (2012-11-06)

The use of intrauterine devices as a contraceptive method has been steadily growing in developing countries. Anemia in reproductive-age women is a growing concern in those settings. A systematic review of studies with measured hemoglobin and serum ferritin at baseline

View All Related Papers

Global Trade Item Number

SKU	GTIN
1362602-125MG	04061838731265

Questions

Reviews

No rating value